Atugen is a leader in RNAi therapeutics. This Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi") and a proprietary delivery system ("AtuPLEX") both of which have advantages over conventional siRNA molecules and their delivery systems. Currently Atugen and its collaboration partners have lead molecules in preclinical development for a variety of therapeutic indications. Clinical development of AtuRNAi therapeutic molecules for systemic applications in Atugen's oncology programs are targeted to start in 2007. Other clinical AtuRNAi therapeutic programs of Atugen's collaborators are scheduled to commence in 2H 2006.
View Top Employees from Atugen AG| Website | http://www.atugen.com |
| Revenue | $4 million |
| Employees | View employees |
| Address | 2950 Wilderness Pl, Boulder, Colorado 80301, US |
| Phone | +49 30 94892800 |
| Industry | Biotechnology, Pharmaceuticals, Healthcare |
| Competitors | BIONOMICS LIMITED, Benitec Biopharma Inc., Lexicon Pharmaceuticals, Inc., SYLENTIS, Sirnaomics |
| SIC | SIC Code 58 Companies, SIC Code 581 Companies |
| NAICS | NAICS Code 722513 Companies, NAICS Code 72251 Companies, NAICS Code 72 Companies, NAICS Code 7225 Companies, NAICS Code 722 Companies |
Looking for a particular Atugen AG employee's phone or email?
Atugen AG Questions
The Atugen AG annual revenue was $4 million in 2023.
Atugen AG is based in Boulder, Colorado.
The NAICS codes for Atugen AG are [722513, 72251, 72, 7225, 722].
The SIC codes for Atugen AG are [58, 581].
